These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 11980004)
1. [Practical impact of pharmacologic and clinical data on early post-operative instillation of mitomycin C]. Bonnal JL Prog Urol; 2002 Feb; 12(1):118-23. PubMed ID: 11980004 [TBL] [Abstract][Full Text] [Related]
2. [Early postoperative mitomycin C instillation: when and how?]. Traxer O; Gattegno B Prog Urol; 2004 Apr; 14(2):249-51. PubMed ID: 15217151 [TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Järvinen R; Kaasinen E; Sankila A; Rintala E; Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154 [TBL] [Abstract][Full Text] [Related]
4. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection. Shapiro O; Jones K; Wang C; Landas S; Haas GP Can J Urol; 2006 Dec; 13(6):3317-20. PubMed ID: 17187694 [TBL] [Abstract][Full Text] [Related]
5. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. Divrik RT; Yildirim U; Zorlu F; Ozen H J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720 [TBL] [Abstract][Full Text] [Related]
6. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696 [TBL] [Abstract][Full Text] [Related]
7. Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C. Stoehr B; Mueller T; Granig T; Zangerl F; Steiner H BJU Int; 2008 Dec; 102(11):1556-9. PubMed ID: 18691179 [TBL] [Abstract][Full Text] [Related]
8. Single instillation of mitomycin C reduces 1st year recurrence following transurethral resection of non-muscle invasive bladder cancer. Ather MH; Aziz S; Sulaiman MN J Ayub Med Coll Abbottabad; 2007; 19(4):18-20. PubMed ID: 18693589 [TBL] [Abstract][Full Text] [Related]
9. Increasing medical staff safety by using a closed system for intravesical instillation of mitomycin C. Haifler M; Lang E; Sabler I; Gutman Y; Lindner A; Zisman A Urology; 2010 Sep; 76(3):649-51. PubMed ID: 20493518 [TBL] [Abstract][Full Text] [Related]
10. [Lung sarcoidosis following instillation of mitomycin C in the urinary bladder]. Cuervo Pinna MA; Cuervo Pinna C; Macías Castillo S; Bureo Dacal JC; Espada Alonso MJ; Pimentel Leo J An Med Interna; 2001 Dec; 18(12):641-3. PubMed ID: 11852501 [TBL] [Abstract][Full Text] [Related]
11. Intravesical mitomycin C for superficial transitional cell carcinoma. Bolenz C; Cao Y; Arancibia MF; Trojan L; Alken P; Michel MS Expert Rev Anticancer Ther; 2006 Aug; 6(8):1273-82. PubMed ID: 16925493 [TBL] [Abstract][Full Text] [Related]
12. Drug eruption due to intravesical instillations of both epirubicin and mitomycin C. Okumura A; Oishi N; Kaji K; Imamura T; Fuse H J Dermatol; 2009 Jul; 36(7):419-22. PubMed ID: 19583691 [TBL] [Abstract][Full Text] [Related]
13. Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system. Feifer A; Xie X; Brophy JM; Segal R; Kassouf W Urology; 2010 Sep; 76(3):652-6. PubMed ID: 20394970 [TBL] [Abstract][Full Text] [Related]
14. [Bladder necrosis after an immediate post-operative mitomycin C instillation]. Branchereau J; Luyckx F; Hitier M; Karam G; Bouchot O; Rigaud J Prog Urol; 2011 Feb; 21(2):151-3. PubMed ID: 21296285 [TBL] [Abstract][Full Text] [Related]
15. Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases. Engeler DS; Wyler S; Neyer M; Hobi C; Müller J; Schmid HP Scand J Urol Nephrol; 2008; 42(6):522-7. PubMed ID: 18609290 [TBL] [Abstract][Full Text] [Related]
16. The MRC superficial bladder cancer trial of intravesical mytomicin-c after complete surgical resection. Sequential statistical methods applied to survival data from a randomised clinical trial. Donaldson AM; Gonzalez JG; Parmar MK; Donaldson N Int J Surg; 2009 Oct; 7(5):441-5. PubMed ID: 19486950 [TBL] [Abstract][Full Text] [Related]
17. Perivesical inflammation and necrosis due to mitomycin C instillation after transurethral resection of bladder tumor: we must be vigilant! Fazlioglu A; Tandogdu Z; Kurtulus FO; Parlakkilic O; Cek M Urol Int; 2009; 83(3):362-3. PubMed ID: 19829042 [TBL] [Abstract][Full Text] [Related]
18. [Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents]. Lingnau A; Miller K; Steiner U; Jentzmik F; Weikert S; Schostak M Aktuelle Urol; 2009 Sep; 40(5):307-9. PubMed ID: 19637135 [TBL] [Abstract][Full Text] [Related]
19. Chemo-prevention in superficial bladder cancer using mitomycin C: a survey of the practice patterns of British urologists. Clarke NS; Basu S; Prescott S; Puri R BJU Int; 2006 Apr; 97(4):716-9. PubMed ID: 16536760 [TBL] [Abstract][Full Text] [Related]
20. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. Mostafid AH; Rajkumar RG; Stewart AB; Singh R BJU Int; 2006 Mar; 97(3):509-12. PubMed ID: 16469017 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]